Valiant Laboratories Limited VALIANTLAB NSEPHARMA
Company Overview
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also manufactures and sells specialty chemicals and chemical intermediates, including chlorophenol derivatives, benzene-based specialty chemicals and other chemical intermediates to agrochemicals, pharmaceuticals, dyes and pigments, polymers, personal care, and allied industries. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India.
Why Investors Should Care
Trades at a P/E of 37.6, below the sector median of 40.0.
Operating margin of 22.9% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Mar 2026 Revenue of ₹237.47 Cr (+78.0% YoY); net profit ₹-3.27 Cr.
- Trailing 12 Months Year-on-year growth — revenue +146.2%, earnings +826.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -10.7%, profit CAGR -37.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -10.74% |
| 1 Year: | 146.20% |
Compounded Profit Growth
| 5 Years: | -37.09% |
| 1 Year: | 826.20% |
Stock Price Performance
| 1 Year: | +16.44% |
| 6 Months: | +95.62% |
| 3 Months: | +45.52% |
| 1 Month: | +72.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)70.93 · Overbought
P/E of 37.58 is below the sector median of 40.02 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -10.7% CAGR over 5 years.
- Earnings shrank at -37.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VALIANTLAB Valiant Laboratories Limited NSEPHARMA | 105.97 | 37.58 | ₹575.55 Cr | 0.00% | 0.78% | -1.05% | -10.74% | -37.09% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,895.00 | 37.64 | ₹4.55 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,315.00 | 84.60 | ₹2.47 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,914.00 | 78.62 | ₹1.87 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 688.00 | 237.24 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,156.90 | 23.10 | ₹1.16 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 33.25 | ₹1.12 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 90.86 | ₹99,417.45 Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 57.79 Cr | 46.82 Cr | 46.20 Cr | 52.46 Cr | 91.98 Cr |
| Cost of Revenue | - | 48.23 Cr | 39.72 Cr | 40.33 Cr | 44.97 Cr | 72.13 Cr |
| Gross Profit | - | 9.56 Cr | 7.10 Cr | 5.87 Cr | 7.49 Cr | 19.85 Cr |
| Operating Expenses | - | 6.25 Cr | 5.23 Cr | 6.33 Cr | 10.43 Cr | 17.97 Cr |
| Operating Income | - | 3.31 Cr | 1.87 Cr | -45.37 L | -2.94 Cr | 1.89 Cr |
| EBITDA | - | 1.51 Cr | 3.05 Cr | 94.46 L | -26.01 L | 4.98 Cr |
| Interest Expense | - | 5.45 L | 7.33 L | 13.59 L | 68.21 L | 1.01 Cr |
| Pretax Income | - | 93.91 L | 2.45 Cr | 27.65 L | -2.99 Cr | 1.05 Cr |
| Tax Provision | - | 23.53 L | 62.79 L | 7.64 L | 4.07 Cr | -71.19 L |
| Net Income | - | 70.36 L | 1.82 Cr | 20.01 L | -7.06 Cr | 1.76 Cr |
| Diluted EPS | - | 0.16 | 0.39 | 0.04 | -1.44 | 0.32 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 333.91 Cr | 182.06 Cr | 133.38 Cr | 237.47 Cr |
| Cost of Revenue | - | 284.71 Cr | 176.52 Cr | 116.60 Cr | 197.16 Cr |
| Gross Profit | - | 49.20 Cr | 5.54 Cr | 16.78 Cr | 40.30 Cr |
| Operating Expenses | - | 15.62 Cr | 15.91 Cr | 23.55 Cr | 39.95 Cr |
| Operating Income | - | 33.58 Cr | -10.38 Cr | -6.77 Cr | 35.02 L |
| EBITDA | - | 39.95 Cr | 1.27 Cr | 75.53 L | 8.71 Cr |
| Interest Expense | - | 25.37 L | 7.78 L | 17.53 L | 1.90 Cr |
| Pretax Income | - | 38.14 Cr | -76.95 L | -1.51 Cr | 76.82 L |
| Tax Provision | - | 9.14 Cr | -1.09 Cr | 68.86 L | 4.04 Cr |
| Net Income | - | 29.00 Cr | 31.96 L | -2.20 Cr | -3.27 Cr |
| Diluted EPS | 5.87 | 6.19 | 0.12 | -0.51 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 212.97 Cr | 342.69 Cr | 400.86 Cr | 463.98 Cr |
| Current Assets | - | 150.58 Cr | 225.54 Cr | 192.62 Cr | 228.32 Cr |
| Cash & Equivalents | - | 1.26 Cr | 11.72 Cr | 4.92 Cr | 3.53 Cr |
| Inventory | - | 13.04 Cr | 10.02 Cr | 3.99 Cr | 45.43 Cr |
| Receivables | - | 88.57 Cr | 45.72 Cr | 72.12 Cr | 93.56 Cr |
| Total Liabilities | - | 112.47 Cr | 105.83 Cr | 166.55 Cr | 153.09 Cr |
| Current Liabilities | - | 50.73 Cr | 29.08 Cr | 59.62 Cr | 119.45 Cr |
| Long Term Debt | - | 59.40 Cr | 74.66 Cr | 104.35 Cr | 28.09 Cr |
| Total Debt | - | 60.22 Cr | 76.71 Cr | 121.69 Cr | 46.21 Cr |
| Total Equity | - | 100.49 Cr | 236.86 Cr | 234.31 Cr | 310.89 Cr |
| Shares Outstanding | - | 4.68 Cr | 4.68 Cr | 4.68 Cr | 5.43 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 56.05 Cr | 1.89 Cr | 1.31 Cr | -10.43 Cr |
| Investing Cash Flow | - | -55.17 Cr | -143.88 Cr | -52.77 Cr | 7.25 Cr |
| Financing Cash Flow | - | -93.39 L | 152.45 Cr | 44.65 Cr | 1.79 Cr |
| Capital Expenditure | - | -37.68 Cr | -45.87 Cr | -113.85 Cr | -34.20 Cr |
| Free Cash Flow | - | 18.37 Cr | -43.98 Cr | -112.54 Cr | -44.63 Cr |
| Net Change in Cash | - | -5.10 L | 10.46 Cr | -6.80 Cr | -1.39 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 14.7% | 3.0% | 12.6% | 17.0% |
| Operating Margin % | - | 10.1% | -5.7% | -5.1% | 0.1% |
| Net Margin % | - | 8.7% | 0.2% | -1.7% | -1.4% |
| ROE % | - | 28.9% | 0.1% | -0.9% | -1.1% |
| ROCE % | - | 20.7% | -3.3% | -2.0% | 0.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VALIANTLAB
VALIANTLAB Mar 2026 Earnings: Moderate profit amid steady revenue; stock sees slight dip - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQTmx6LWhqWklkU2Fla3Zua1cyN3A2LWU2YkFJcE4tQW8tbWJ0VFV4MnIzSHRMQUJ5RXQyaFlXYmlja29FSlA3ckRmQlVDNHYyWFExQnVUbzhxLXR2eWZNczJKN2VRWmtHaFNZbjdOemRQM3pCT2p6dXVrVThubFpLNmtQUWJuY2MzM3dxR3…
VALIANTLAB Mar 2026 Earnings: Positive EPS of ₹0.65 on Revenue of ₹65.3 Crore; Stock Declines Marginally - Estimate Uncertainty - siam.in
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPSUw0aUlYTE9ObjNRRW9vTXNVdWhJODBDNWRGd1A3c01peWc2OUxSUjNPRHR1Yk93am1TWDRUbVNWR1ljdzRaS0Q5aFQzQjRmMTd4T1ZNRTNYNTJJa1N5bmZDRTFlSFExMGRGT2tRNlZYUDdsY1BNTEptTlB5WEtLaVBBUmcyamdPbkt5c0…
Valiant Laboratories Edges Lower, Tests Key Support Near ₹64.5 - Backspread Trade - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOX1dmNDhSRzA3TlRLaU5ULVZsR3ZSb21YSHVObVFPRWRkTXdYR1lCVld3d2gteGFqeHRoX2otc2JOajROd3BuUHFUWEtlVDJtRlEzZFRjUkt6MGtuN3JHOVU2ZDVTZUFlVUJXM1M2azY1c2J6QUUwX0FpUVpvbndGTU56OWsza2xiV0xlV0…
Valiant Laboratories Recovers From Support, Tests Key Resistance Near ₹79.7 - Breakout Trade - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQVWFBTXFsUE9xY3dLY05DTDZ1elhoMGJRQkhxcllTU3dHQUxWVTNLQjQwN3B6d1h4RTFrSTJ3c2xOYkNTWktZQktzeUFoeGdrUVlRNXByeHZLN3BNem9JdXVKRDRyYXFMdGJFckNDVkRpWnd6QUgtWmNobWJNMXpiSFNycHQ4cFJZdHNQRH…
Valiant Laboratories Mar 2026 Earnings: Revenue of ₹65.3 crore and EPS of ₹0.65; Stock edges lower - Guidance Accuracy Score - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQWFctX0ZIWS1JWHlKYkhUUXJjRWd4VXZueVFXMmtjS004aVJ4REtFSGxGZzFMU1BtcVBPOWFTZ2hiMm42WHdLSDYwU0p4SkJoakstRTQ0eFNOSU9YRGN3b2ZaaXJpVUQyeUhWbDI1YXpSeTV1R3VjM1pFTjU2WV8weWdUbG00dWs5OW5MVm…
VALIANTLAB.NS Mar 2026 Earnings: Modest Profitability Amidst Stable Revenue - Revenue Growth Report - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNR0NqSTlrbXMxWjFuOHRnTU9pYkx5al9TZm9IYU9uUW9KWHdQeXdkNzI2eHVxUmtEeGVZYmEyc1dBcFRaOE9qZ3pTNHpOZHRramRweG10b3c2QkVHYjE3ZERwamVDaWFHTXplYjZMNzR4NkU1dzgyT2FIWHJodjl3X0JEU19ZMlVhbnV1U2…
VALIANTLAB — Frequently Asked Questions
What is the current share price of Valiant Laboratories Limited (VALIANTLAB)?
As of 2026-09-20 09:43 IST, Valiant Laboratories Limited (VALIANTLAB) trades at ₹105.97 on NSE. Its 52-week range is ₹50.93 to ₹107.87.
What is the market capitalisation of VALIANTLAB?
Valiant Laboratories Limited (VALIANTLAB) has a market capitalisation of ₹575.55 Cr on NSE.
What is the P/E ratio of VALIANTLAB?
VALIANTLAB trades at a trailing price-to-earnings (P/E) ratio of 37.58. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 2.12.
What is the return on equity (ROE) of VALIANTLAB?
VALIANTLAB has a return on equity (ROE) of -1.05%. Its return on capital employed (ROCE) is 0.78%.
Is VALIANTLAB a good stock to buy?
This page provides a data-driven analysis of Valiant Laboratories Limited (VALIANTLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.